AsraZeneca has entered an agreement with Grünenthal to divest the rights to its migraine treatment Zomig outside Japan.
Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca’s strategic focus.
Grünenthal – who will pay AstraZeneca $200 million upon completion – will acquire the rights to Zomig in all markets outside Japan, including the US, where the rights were previously licensed to Impax Pharmaceuticals.
Impax will continue to market Zomig in the US. AstraZeneca will continue to manufacture and supply the medicine to Grünenthal during a transition period.
Gabriel Baertschi, CEO of Grünenthal, said: “Migraine is a very debilitating disease with more than 75 million people worldwide suffering from attacks that can lead to sensitivity to light or sound, to nausea or even vomiting. The acquisition of the well-established Zomig products complements our existing pain portfolio.
“Migraine has been one of the very few main pain indications we haven’t yet been able to offer a solution for. This is an important step to reach our ambition to become a €2 billion company by 2022.
“It will also support our efforts to bring four to five innovative products to market in the same timeframe.”